Drug Trial Radar · NCT04082364
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
Last checked: Nov 20, 2026Latest source record: Jun 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Sep 30, 2019
Primary completion
Jan 15, 2024
Study completion Mar 25, 2025
Sponsor
- Lead sponsor
- MacroGenicsIndustry
- Sponsor type
- Industry
- Collaborators
- Zai Lab (Shanghai) Co., Ltd.
- First posted
- Sep 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2/3, randomized, open-label study for the treatment of patients with HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer conducted in two parts. Part A is a single-arm cohort (Cohort A, 40 to 110 participants) will evaluate safety and efficacy of margetuximab plus retifanlimab. Part B Part 1 has 4 arms (50 patients/arm). Participants will be randomized to margetuximab plus retifanlimab plus chemotherapy, margetuximab plus tebotelimab, plus chemotherapy, margetuximab plus chemotherapy, or trastuzumab plus chemotherapy.
Conditions
- Gastric Cancer
- Gastroesophageal Junction Cancer
- HER2-positive Gastric Cancer
Interventions
margetuximabBiological
margetuximab: Fc-modified anti-HER2 monoclonal antibody: 15 mg/kg IV, Day1 of each 3-week cycle
RetifanlimabBiological
Retifanlimab: anti-PD-1 checkpoint inhibitor 375 mg IV, Day 1 of each 3-week cycle.
TebotelimabBiological
Tebotelimab: anti PD-1, anti-LAG3 bispecific DART (R) molecule 600 mg IV, Day 1 of each 3-week cycle.
TrastuzumabBiological
Anti-HER2 monoclonal antibody 8 mg/kg loading dose and then 6 mg/kg administered IV on Day 1 of each 3-week cycle
ChemotherapyOther
Investigator choice of 1 of 2 chemotherapy regimens: XELOX or mFOLFOX6 Chemotherapy XELOX chemotherapy Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion mFOLFOX6 chemotherapy: Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events of Margetuximab Plus Retifanlimab in Cohort A, as Assessed by CTCAE v5.0Time frame: Throughout the study, an average of 11 months.
- Objective Response Rate (ORR) for Non-microsatellite Instability-high (Non-MSI-H) Participants (Cohort A) Using Investigator-assessed Radiology ReviewsTime frame: Throughout the study, an average of 11 months.
Locations
73 sites in 9 countries. Site status is shown where the registry gives one.
Mayo Clinic - Scottsdale
Scottsdale, Arizona
City of Hope Comprehensive Cancer Center - Duarte
Duarte, California
Norris Comprehensive Cancer Center (USC)
Los Angeles, California
Salinas Memorial
Salinas, California
UCLA School of Medicine
Santa Monica, California
Yale University
New Haven, Connecticut
Florida Cancer Specialists South
Fort Myers, Florida
Mayo Clinic - Jacksonville
Jacksonville, Florida
Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala
Ocala, Florida
Florida Cancer Specialists North
St. Petersburg, Florida
Kaiser Permanente
Honolulu, Hawaii
University of Chicago
Chicago, Illinois
Edward H. Kaplan MD & Associates
Skokie, Illinois
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion
Grand Rapids, Michigan
Mayo Clinic - Rochester
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Nebraska Heme Onc
Lincoln, Nebraska
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
The University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico
Stephenson Cancer Center at OUHSC
Oklahoma City, Oklahoma
Sarah Cannon Research Institute
Nashville, Tennessee
Oncology Consultants
Houston, Texas
Utah Cancer Specialists
Salt Lake City, Utah
Virginia Cancer Specialists
Fairfax, Virginia
Swedish Cancer Institute
Seattle, Washington
University of Wisconsin
Madison, Wisconsin
Beijing Cancer Hospital
Beijing, China
Jilin Cancer Hospital (Second People's Hospital Of Jilin Province)
Changchun, China
Fujian Medical University - Fujian Provincial Cancer Hospital (Fujian Provincial Tumor Hospital)
Fuzhou, China
SIR RUN RUN SHAW Hospital, Zhejiang University school of medicine
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Affiliated Tumor Hospital of Harbin Medical University- the 3rd Affiliated Hospital of Harbin
Harbin, China
The First Affiliated Hospital of Anhui Medical University
Hefei, China
Anhui Provincial Cancer Hospital
Hefei, China
Jinan Center Hospital
Jinan, China
Nanjing University Medical School; Nanjing Drug Tower
Nanjing, China
Zhongshan Hospital Fudan University
Shanghai, China
Liaoning cancer hospital
Shenyang, China
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.